These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 35861622)
41. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps. Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020 [TBL] [Abstract][Full Text] [Related]
42. Combining biomarkers for classification with covariate adjustment. Kim S; Huang Y Stat Med; 2017 Jul; 36(15):2347-2362. PubMed ID: 28276080 [TBL] [Abstract][Full Text] [Related]
43. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084 [TBL] [Abstract][Full Text] [Related]
44. Identification of biomarkers and potential molecular mechanisms of clear cell renal cell carcinoma. Wu F; Wu S; Gou X Neoplasma; 2018; 65(2):242-252. PubMed ID: 29534586 [TBL] [Abstract][Full Text] [Related]
45. Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma. Simonetti S; Iuliani M; Stellato M; Cavaliere S; Vincenzi B; Tonini G; Santini D; Pantano F J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104102 [TBL] [Abstract][Full Text] [Related]
46. Kidney cancer: When worlds collide--integrating metabolic and transcriptomic data in ccRCC. Thoma C Nat Rev Urol; 2016 Mar; 13(3):126. PubMed ID: 26813954 [No Abstract] [Full Text] [Related]
47. Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation. Peng D; Ge G; Xu Z; Ma Q; Shi Y; Zhou Y; Gong Y; Xiong G; Zhang C; He S; He Z; Li X; Ci W; Zhou L Epigenomics; 2018 Sep; 10(9):1189-1199. PubMed ID: 30182734 [TBL] [Abstract][Full Text] [Related]
48. [Possibilities of molecular diagnosis of renal cell carcinoma]. Junker K Aktuelle Urol; 2014 Sep; 45(5):370-3. PubMed ID: 25230022 [TBL] [Abstract][Full Text] [Related]
49. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma. Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693 [TBL] [Abstract][Full Text] [Related]
50. Facial fibrofolliculomas as indicator for renal cell cancer. Johannesma PC; Starink TM; Van Moorselaar RJ; Postmus PE Jpn J Clin Oncol; 2014 Jun; 44(6):609-10. PubMed ID: 24864271 [No Abstract] [Full Text] [Related]
51. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154 [TBL] [Abstract][Full Text] [Related]
52. Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro. Zieren RC; Dong L; Clark DJ; Kuczler MD; Horie K; Moreno LF; Lih TM; Schnaubelt M; Vermeulen L; Zhang H; de Reijke TM; Pienta KJ; Amend SR Med Oncol; 2021 Jul; 38(9):105. PubMed ID: 34331598 [TBL] [Abstract][Full Text] [Related]
53. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. Alymani NA; Smith MD; Williams DJ; Petty RD Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504 [TBL] [Abstract][Full Text] [Related]
54. Tissue biomarkers in renal cell carcinoma: issues and solutions. Di Napoli A; Signoretti S Cancer; 2009 May; 115(10 Suppl):2290-7. PubMed ID: 19402057 [TBL] [Abstract][Full Text] [Related]
55. Biomarkers of renal cell carcinoma. Ngo TC; Wood CG; Karam JA Urol Oncol; 2014 Apr; 32(3):243-51. PubMed ID: 24239464 [TBL] [Abstract][Full Text] [Related]
56. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382 [TBL] [Abstract][Full Text] [Related]
57. Atypical Renal Cysts: A Morphologic, Immunohistochemical, and Molecular Study. Matoso A; Chen YB; Rao V; Wang L; Cheng L; Epstein JI Am J Surg Pathol; 2016 Feb; 40(2):202-11. PubMed ID: 26574846 [TBL] [Abstract][Full Text] [Related]
58. A direct method to evaluate the time-dependent predictive accuracy for biomarkers. Shen W; Ning J; Yuan Y Biometrics; 2015 Jun; 71(2):439-49. PubMed ID: 25758584 [TBL] [Abstract][Full Text] [Related]
59. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. White NM; Bao TT; Grigull J; Youssef YM; Girgis A; Diamandis M; Fatoohi E; Metias M; Honey RJ; Stewart R; Pace KT; Bjarnason GA; Yousef GM J Urol; 2011 Sep; 186(3):1077-83. PubMed ID: 21784468 [TBL] [Abstract][Full Text] [Related]
60. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status. Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]